Non-Clinical In-vitro and In-vivo Studies in Drug Development

The process of discovering and developing drugs is intricate involving multiple stages of critical importance, from basic research to FDA approval. sequence of steps involved, namely Fundamental Investigation, Preliminary Development, Clinical Testing, and FDA Submission/Authorization. Each stage incorporates major scientific and regulatory assessments, including lead identification, toxicity studies, pharmacological profiling, and clinical testing, spanning Phases I–III. Additionally, Good Laboratory Practice (GLP), Good Manufacturing Practice (GMP), Good Clinical Practice (GCP) at different stages. systematic flow indicates the significance of iterative feedback loops between stages to guarantee safety, efficacy, and regulatory compliance, ultimately leading to the introduction of secure and efficient treatment options to the market.

Authors

Institutions

Publication Details

Journal
International Journal of Drug Regulatory Affairs
Published
2025-06-15
DOI
https://doi.org/10.22270/ijdra.v13i2.756
Primary Topic
Biosimilars and Bioanalytical Methods
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Non-Clinical In-vitro and In-vivo Studies in Drug Development

Tahir Rasheed, Abdul Mannan, Zoya Nousheen
International Journal of Drug Regulatory Affairs
Biosimilars and Bioanalytical Methods
article

Non-Clinical In-vitro and In-vivo Studies in Drug Development

Tahir Rasheed, Abdul Mannan, Zoya Nousheen
article en

Abstract

The process of discovering and developing drugs is intricate involving multiple stages of critical importance, from basic research to FDA approval. sequence of steps involved, namely Fundamental Investigation, Preliminary Development, Clinical Testing, and FDA Submission/Authorization. Each stage incorporates major scientific and regulatory assessments, including lead identification, toxicity studies, pharmacological profiling, and clinical testing, spanning Phases I–III. Additionally, Good Laboratory Practice (GLP), Good Manufacturing Practice (GMP), Good Clinical Practice (GCP) at different stages. systematic flow indicates the significance of iterative feedback loops between stages to guarantee safety, efficacy, and regulatory compliance, ultimately leading to the introduction of secure and efficient treatment options to the market.

International Journal of Drug Regulatory AffairsVol. 13(2)
Deccan College of Medical Sciences (IN), Deccan School of Hospital Management (IN)
Openalex Percentile: Top 80%
Biosimilars and Bioanalytical Methods
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Non-Clinical In-vitro and In-vivo Studies in Drug Development — Tahir Rasheed, Abdul Mannan, et al. · International Journal of Drug Regulatory Affairs (2025) | TGRS Research Map | TGRS